By Dr. Benjamin Caplan, MD | Board-Certified Family Physician, CMO at CED Clinic | Evidence Watch
Want to apply this research to your care?
CED Clinic translates emerging research into individualized clinical care. Dr. Caplan has treated 30,000+ patients.
Book a consultation →A randomised crossover trial of 35 cannabis users found that vaporising cannabis containing both CBD and THC led to significantly higher THC blood levels than vaporising THC alone. This challenges previous inhalation studies and raises important questions about how CBD-containing cannabis products may alter THC exposure, with potential implications for dosing, safety, and drug-impairment assessments.
CBD in Vaporised Cannabis Boosts THC Levels in the Blood, Study Finds
A double-blind crossover trial shows co-inhaling CBD with THC raises plasma THC and metabolite concentrations, contradicting several prior inhalation studies and uniquely including adolescents in the pharmacokinetic analysis, with no clear age differences observed between teens and adults.
#72
Strong Clinical Relevance
Addresses a directly actionable pharmacokinetic question for clinicians and patients using CBD-THC combination cannabis products, though findings await replication.
CBD-THC Interaction
Vaporised Cannabis
Adolescent Health
Crossover RCT
The assumption that CBD is pharmacologically “neutral” alongside THC has shaped product formulation, clinical dosing guidance, and even forensic interpretations of THC impairment. If CBD reliably increases THC blood levels when inhaled together, the implications extend from patient safety and therapeutic dose management to roadside drug testing and cannabis product labelling. The finding is especially pressing because combination CBD-THC products are increasingly common in both medical and recreational markets, and clinicians and regulators have lacked clear pharmacokinetic data on what happens when these compounds are co-inhaled.
Whether CBD modifies THC pharmacokinetics when the two are inhaled together has remained uncertain, with prior studies producing contradictory results. The biological rationale centers on CBD’s known inhibition of cytochrome P450 enzymes (particularly CYP2C9 and CYP3A4) that metabolize THC, which could slow THC clearance and elevate systemic exposure. This secondary analysis from the CannTeen Acute trial used a well-controlled crossover design with weight-adjusted dosing of vaporised cannabis products, comparing three conditions within each participant: THC alone (8 mg per 75 kg), THC plus CBD at a 3:1 CBD-to-THC ratio (24 mg CBD plus 8 mg THC per 75 kg), and placebo. The study enrolled both adolescents aged 16 to 17 and adults aged 26 to 29, a unique inclusion that allowed exploratory age comparisons.
Among 35 participants with complete pharmacokinetic data, the THC-plus-CBD condition produced significantly higher area-under-the-curve (AUC) values and peak concentrations (Cmax) for THC and its primary metabolites, OH-THC and COOH-THC, compared to THC alone, with the exception of Cmax for OH-THC which did not reach statistical significance. No strong evidence of age-related pharmacokinetic differences emerged, though this comparison was likely underpowered. Critical limitations include only four blood sampling time points, which constrains the precision of AUC estimation and true Cmax identification, the non-pre-registered nature of this secondary analysis, and the 3:1 CBD-to-THC ratio which may not reflect typical consumer products. The authors appropriately note that replication with denser sampling is needed before these findings can be considered definitive.
This study does something valuable by using a rigorous crossover design and standardized dosing to address a question I hear from patients constantly: does the CBD in their cannabis product change how the THC hits them? The finding that CBD may actually increase THC blood levels is pharmacologically plausible and clinically important if it holds up. But I am cautious here. The sparse blood sampling, the non-pre-registration, and the direct contradiction with at least three other inhalation studies all tell me we are not ready to treat this as settled science. One well-done trial is not a consensus, and the 3:1 CBD-to-THC ratio used here is not what most of my patients are consuming.
In my practice, I already counsel patients that CBD-THC interactions are complex and potentially bidirectional. When someone is titrating a combination product, I advise starting lower than they might expect and paying close attention to both subjective and physiological responses. This study reinforces that approach. I do not change dosing algorithms based on a single secondary analysis, but I do use findings like this to explain to patients why their experience with a “balanced” product might feel stronger than pure THC at the same nominal dose, and why that warrants respect.
This study sits at an inflection point in the cannabinoid pharmacokinetics literature. The oral route data have generally supported CBD’s inhibition of THC metabolism at high doses, but the inhalation literature has been more equivocal, with several well-designed trials (including Englund et al., 2023) finding no significant interaction. The present study introduces a credible counterpoint, but the conflict itself should be the dominant takeaway for practicing clinicians. We do not yet know whether the discrepancy reflects dose ratios, vaporization temperature differences, sampling methodology, or genuine biological heterogeneity. Until additional studies with denser pharmacokinetic sampling replicate these findings, clinicians should not assume a fixed directional effect of CBD on inhaled THC exposure.
From a safety perspective, the possibility that CBD amplifies THC exposure is relevant for patients using high-CBD cannabis products who may be at risk for THC-related adverse effects including anxiety, tachycardia, or cognitive impairment. It also has implications for forensic tox
